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ABSTRACT 
Objectives: During routine diagnostic laboratory work, the clinical microbiologist observed 
an increase of Acinetobacter baumannii isolates with three different carbapenem 
susceptibility patterns : susceptible, intermediate and resistant.  Isolates belonging to the same 
carbapenem susceptibility phenotype exhibited identical susceptibility/resistance patterns to 
non-β-lactam antibiotics. This prompted us to analyze the mechanisms of carbapenem-
resistance and the molecular epidemiology of the isolates. A total of 59 A. baumannii isolates 
were analyzed and grouped according to their susceptibility to imipenem: group 1 were 
susceptible (N=24), group 2 were intermediate (N=8) and group 3 were resistant (N=27) to 
imipenem. 
Material and methods: PCR and sequencing was used to detect resistance genes. Genotyping 
of the isolates was performed by PFGE and MLST.  
Results : Out of  27 resistant isolates, 20 harboured blaOXA-40-like and 7 blaOXA-23-like genes. 
ISAba1 was found upstream of blaOXA-51 and blaOXA-23 genes. PFGE genotyping demonstrated 
the existence of three major A. baumannii clones in GH Pula and determination of sequence 
groups  showed that the isolates belonged to international clones commonly associated with 
multidrug-resistance. MLST (performed on six isolates) showed diverse population structure 
of isolates belonging to the same cluster, including ST 195,  ST 231, ST 775 and ST1095.  
Conclusions: A previous study conducted in 2009-2010 showed that reduced susceptibility to 
carbapenems in GH Pula was only associated with upregulation of the intrinsic OXA-51 β-
lactamase. In this study a shift to isolates with acquired oxacillinases, belonging to two major 
clones was reported. 
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1. INTRODUCTION 
Acinetobacter baumannii is a Gram-negative opportunistic pathogen causing infections in 
health care settings globally [1].  As an emerging pathogen it represents a serious public 
health concern owing to its increasingly multidrug-resistant capacity [2]. Carbapenem-
resistance can develop due to hyperproduction of chromosomally encoded OXA-51-like β-
lactamase mediated by ISAba1 upstream of the blaOXA-51 genes. Rarely, resistance can occurr 
because of porin loss (CarO) or overexpression of efflux pumps [3].  Acquired carbapenem 
resistance in A. baumannii can also be mediated by acquired carbapenemases of class A 
(KPC) [4], metallo-β-lactamases (MBLs) of IMP, VIM, SIM and NDM family [5-8] and 
carbapenem-hydrolyzing oxacillinases (CHDL) (OXA-23-like, OXA-40-like, OXA-58-like, 
OXA-143-like and OXA-235-like [9-12].  From 2008 carbapenem-resistant A. baumannii 
emerged with increasing frequency in most hospital centers in Croatia and became an 
important public health problem as shown by the multicenter study conducted in Northern 
Croatia and Istria demonstrating that OXA-40-like and OXA-58-like were the dominant types 
of acquired CHDL in Croatia. However,  reduced susceptibility to carbapenems among Istrian 
isolates, belonging to ST1,  was due to of the intrinsic OXA-51 β-lactamase upregulated by 
ISAba1  [13]. Unlike other geographic regions, Istria county located in the southwest part of 
Croatia was spared of acquired carbapenemases until recently. During routine diagnostic 
laboratory work, the clinical microbiologist observed the  emergence of carbapenem-resistant 
A. baumannii isolates , alongside with persistence of previous susceptibile or intermediate 
susceptible ones and classified them into three categories; susceptible, intermediate and 
resistant.  Isolates belonging to the same carbapenem susceptibility  group  exhibited identical 
susceptibility/resistance patterns to non-β-lactam antibiotics. The three groups circulated in 
different hospital wards during the study period (2013-2014). This prompted us to analyze the 
4 
 
underlying mechanisms of carbapenem-resistance and the molecular epidemiology of isolates 
with various antibiotic susceptibility profiles.  
2. MATERIAL AND METHODS 
2.1.Material and methods 
A total of 59 consecutive A. baumannii isolates collected between May 2012 and August 2014 
were analyzed. The isolates were tentatively identified to species level by VITEK2 automated 
system,  and confirmed by gyrB multiplex PCR and the  presence of the intrinsic blaOXA-51 
gene [14].  
2.2.Antimicrobial susceptibility testing 
The antimicrobial susceptibility to a wide range of β-lactam antibiotics including ceftazidime 
(CAZ), cefotaxime (CTX), ceftriaxone (CRO), cefepime (FEP), imipenem (IMP), meropenem 
(MEM) and non-β-lactam antibiotis such as gentamicin (GEN), amikacin (AMK), 
ciprofloxacin (CIP), tigecycline (TGC) and colistin (COL) was determined by broth 
microdilution in Mueller-Hinton broth in 96-well microtiter plates according to CLSI 
guidelines [15]. Pseudomonas aeruginosa  ATCC 27853 and A. baumannii  ATCC 19606 
were used as quality control strain.  E-test MBL strips  (AB Biodisk, Solna, Sweden) and 
combined disk test with EDTA  were used for detection of metallo-β-lactamases (MBL) [16]. 
Extended-spectrum β-lactamases were detected by  double disk synergy test (DDST) 
according to Jarlier and combined disk test with the addition of cloxacillin in the medium to 
inhibit chromosomal AmpC β-lactamase of A. baumannii [17].  Escherichia coli ATCC 
25922 and Klebsiella pneumoniae  ATCC 700603 were used as negative and positive control 
strains, respectively.   
2.3.Molecular characterization of β-lactamases 
The presence of the genes encoding KPC, MBLs of IMP, VIM, SIM and NDM  class  [4, 5-8] 
and OXA β-lactamases (blaOXA-51-like, blaOXA-23-like, blaOXA-40-like, blaOXA-58-like and blaOXA-143-
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like) genes [18] was determined  by PCR as previously described. The amplicons of the 
selected representative isolates were column-purified (QIAquick PCR purification kit, Inel 
Medicinska tehnika, Zagreb) and subjected to sequencing by the Macrogen sequencing 
service (South Korea) with the same primers used for PCR in order to determine the identity 
of the enzyme. Sequence alignment analysis was done online by utilizing the BLAST 
Program (www.ncbi.nlm.nih.gov). The genetic context of blaOXA-51 and blaOXA-23 genes was 
further investigated by PCR mapping with primers for ISAba1 combined with forward and 
reverse primers for  blaOXA-51 and blaOXA-23 [19]. Isolates phenotypically positive for extended-
spectrum β-lactamases (ESBLs)  in combined disk test were subjected to PCR with primers 
specific for SHV, TEM, PER-1, GES and CTX-M β-lactamases [20-24]. Reference strains 
positive for OXA-23, OXA-40, OXA-58,  OXA-143, VIM-1, IMP-1,  NDM-1, TEM-1, SHV-
1, PER-1 and CTX-M-15 were used as positive controls for PCR. 
2.4.Characterization of plasmids 
Conjugation experiments were performed using E. coli  J 53 resistant to sodium azide [25].  
To determine if acquired oxacillinase genes were plasmid-encoded, plasmid  DNA was 
extracted from for representative isolates  (ACB 22, ACB 23, ACB 24, ACB, 25 and ACB 26) 
and transferred to Acinetobacter baumannii  ATCC 17978  by electroporation.  Transformants 
were  selected on LB medium containing 100 µg/ml ticarcillin [26] .  
Plasmid incompatibility groups were determined by PCR-based replicon typing (PBRT) 
according to Bertini at al [27]. 
2.5.Molecular typing of isolates 
Sequence groups (SGs 1-3) corresponding to international clonal lineages (IC1-3) 
determination was performed according to the procedure described by Turton et al. [28]. 
PFGE genotyping of XbaI-digested genomic DNA was performed with a CHEF-DRIII- 
system (Bio-Rad); the images were processed using Gel-Compar software, and a dendrogram 
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was computed after band intensity correlation using global alignment with 1.5% optimization 
and UPGMA (unweighted pair-group method using arithmetical averages) clustering [29]. 
The isolates were considered to be clonally related if they showed more than 87% similarity 
in their PFGE patterns. The Oxford MLST scheme was used to type a subset of six isolates, 
belonging to different clusters,  using primers and conditions as described at PubMSLT 
(http://pubmlst.org/abaumannii/).  
RESULTS 
3.1.Bacterial isolates 
All isolates initially identified by VITEK 2 as A. baumannii, were confirmed by molecular  
methods as A. baumannii. Respiratory tract specimens (bronchoalveolar lavage fluid  and 
tracheal aspirates) were the most important source of the tested isolates (35%), followed by 
wound swabs (25%), urine (23%), blood cultures (10%), cerebrospinal fluid and drains (3%),  
respectively (Figure 1). The isolates originated predominantly from intensive care unit (ICU) 
(40%), followed by surgery (32%), internal medicine (23%), neurology (3%) and 
otorhinolaryngology (1.7%). 
3.2.Antimicrobial susceptibility 
Results of antimicrobial testing are summarised in Table 1. High resistance rates were 
observed for CIP (93%), CAZ (87%), FEP (84%), GEN (66%)  IMI(49%) and  MEM (45%). 
TGC  showed good activity with only 28% of resistant isolates (according to the resistance 
breakpoint for Enterobacteriaceae).  There was no resistance observed for colistin as shown in 
Table 1.  
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Table 1.  
Antibiotic susceptibility of Acinetobacter baumannii isolates   
Antibiotic (CLSI breakpoint) mg/L          MIC range             MIC 50  MIC90 Resistant strains (%) 
Ceftriaxone (≥ 64)                   
>256 256 
>256 
59/59 (100) 
Cefotaxime (≥ 64) 
>256 256 
>256 
59/59 (100) 
Ceftazidime (≥ 32) 
2 - >256 128 
   >256 
51/59 (87,3) 
Cefepime (≥ 32) 
2 - 256 32 
32 
50/59 (84,7) 
Imipenem (≥ 8) 
0,25 - 32 8 
   32 
27/59 (45,8) 
Meropenem (≥ 8) 
0,25 - 32 4 
   32 
29/59 (49,2) 
Ciprofloxacin (≥ 4) 
0,25 – 256        128 
>256 
55/59 (93,2) 
Amikacin (≥ 64) 
2 - 256       4 
>256 
 26/59 (44,0) 
Gentamicin (≥ 16) 
1 - 256    16 
>256 
39/24 (66,1) 
Tigecycline (≥ 4)* 
0.25 - 4 2 
4 
        14/59 (28) 
Colistin (≥ 4) 
0.12 - 0,5 0.25 
0.25 
        0/59  (0) 
 
  
*Breakpoint for Enterobacteriaceae is applied 
 
 
 
 Isolates were grouped according to their imipenem-susceptiblity according to CLSI criteria: 
group 1 were imipenem-susceptible (N=24), group 2 intermediate (N=8) and group 3 resistant 
(N=27). 
The imipenem-susceptible group isolates showed resistance to CTX and CRO (intrinsic 
resistance in A. baumannii), and were all susceptible to IMI, COL and  TGC (according to 
breakpoint for Enterobacteriaceae) and  all but one were  susceptible to MEM and AMK. 
They showed moderate resistance rates to ceftazidime and cefepime (67%) and high 
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resistance rate to ciprofloxacin  (83%).  COL  was the most potent antibiotic with MIC90 
values of 0.12 mg/L. 
The imipenem-intermediate group isolates were resistant to CAZ, CTX, CRO and CIP. 
Eighty-seven percent of this group were resistant to FEP and 50% to GEN. The isolates were 
uniformly susceptible to TGC (according to CLSI breakpoints for Enterobacteriaceae), AMK  
and COL. Colistin was the most potent antibiotic with a MIC90 of 0.12 mg/L. IMI and MEM 
displayed MIC90 values of 4 mg/L that were slightly higher than those of TGC (2 mg/L). 
The imipenem-resistant group isolates were multidrug-resistant according to Magiorakos et al 
[30] and were uniformly resistant to expanded-spectrum cephalosporins, CIP and GEN. They 
showed a moderate resistance rate to TGC of 52% (according to CLSI breakpoints for 
Enterobacteriaceae),  but were uniformly susceptible to  COL. The lowest MIC90 was 
observed with COL (0.12 mg/L).  
3.3.Characterization of β-lactamases 
Imipenem susceptible isolates were uniformly negative  in DDST  for detection of ESBLs,  
but  positive in CLSI  combined disk test with clavulanate (augmentation of inhibition  zone 
around cephalosporin disks ranging from 10 to 15 mm). They all tested negative in 
phenotypic test for MBLs. All 59 isolates were PCR positive for the intrinsic blaOXA-51-like 
gene. Eight isolates had only  blaOXA-51 gene without ISAbaI, while in 16 isolates which 
displayed elevated MICs of meropenem (4-8 mg/L)blaOXA-51 gene was preceeded by ISAba.  
All imipenem-intermediate-susceptible isolates tested negative phenotypically for both  
ESBLs and  MBLs. Imipenem-resistant isolates were negative for ESBLs, but the production 
of class B carbapenemases was suspected by positive inhibitor based test with EDTA and at 
least eight fold reduction of imipenem by EDTA MIC in E- test. However,  they were PCR 
negative for the tested MBL genes. Out of 27 isolates, 20 harboured blaOXA-40-like, and 7 
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blaOXA-23-like genes. Sequencing of blaOXA revealed the presence of blaOXA-23 and blaOXA-40 
genes. ISAba1 was found upstream of blaOXA-51 and blaOXA-23 genes.  
3.4.Characterization of plasmids 
ACB22 plasmid preparation transferred OXA-40 while ACB25 plasmid preparation 
transferred OXA-23 into A. baumannii ATCC 17978, leading to carbapenem resistance (data 
not shown).  Other tested isolates did not transfer the CHDL to the recipient strain. The 
plasmids extracted from strains positive for OXA-23 belonged to Inc group 6 encoding aci6-
replicase gene originally found on plasmid pACICU2 (amplicon size 662 bp).  
3.5.Genotyping 
The susceptible and intermediate isolates belonging to  sequence groups (SGs) 1 and 2 were 
assigned to SG 2 corresponding to to IC1,  while isolates resistant to carbapenems (group 3) 
were allocated predominantly to SG 1 corresponding to IC2, apart from isolates 23,  24 and 
30 (IC1, OXA-23 positive) and isolates 34,  37 and 38 (IC1, positive for OXA-40) (Figure 1). 
Three isolates were nontypeable using this method (AB 6, AB, 25 and AB 43).  PFGE 
revealed the existence of three major clusters, summarised in Figure 1: the first dominant  
cluster with 32 isolates contained susceptible or intermediate susceptible obtained from 
different hospital units, positive only for blaOXA-51  with or without ISAba1 and belonging to 
IC I,  with one exception (isolate 26 with OXA-40-like, IC II), and the second and  the third 
cluster included  resistant isolates originating mostly from surgical or ICU wards, positive for 
blaOXA-23-like or blaOXA-40-like, and belonging to  predominantly IC II, with one exception 
(isolate 55, carbapenem susceptible and negative for CHDL).  Subclusters containing pairs,  
triplets or groups of identical isolates were identified within each clone.  Interestingly , some 
of the OXA-23 positive isolates clustered together with OXA-40 positive isolates. Three 
isolates (AB 10, AB 25 and AB 32) were singletons (Figure 1). MLST of six representative 
isolates revealed four different STs: ST-195 (strain 27), ST-231 (strain 38), ST-775 (strains 
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10, 14 and 19), and ST-1095 (isolate 43). Analysis of STs using the PubMLST website 
revealed that ST-195 was associated with IC2, whereas ST-231 and -775 with IC1.  None of 
the isolates belonged to ST1 previously reported among A. baumannii from Istria.  
4.DISCUSSION 
This study demonstrates the existence of at least three different clones of A. baumannii in GH 
Pula. A previous study conducted in 2009-2010 which included 23 isolates from Istria,  
showed that reduced susceptibility to carbapenems in GH Pula was only associated with 
upregulation of intrinsic OXA-51 β-lactamase by ISAba1 located upstream of blaOXA-51 gene. 
In this study a shift to acquired CHDL was reported. The previous isolates from 2009-2010 
belonged uniformly to SG 1 (IC II) and ST1.  The fact that carbapenem-resistant isolates 
originated from patients without travel history or treament hystory in other hospital centers in 
Croatia suggested that these isolates were not imported and arose independently.   
In the present study OXA-23 and OXA-40 β-lactamases were found. OXA-23 was the first 
CHDL reported in 1986 in the UK as ARI-1 [31].  Later it was renamed to OXA-23. It has 
now spread all over the world with most reports originating from Europe and  the Far-East 
[32]. OXA-23 is the dominant CHDL in Bulgaria [33], China [34], Germany [35] , Italy [36] , 
Poland [37], Spain [38], UK [39]  and many other countries [32] and is often associated with 
nosocomial outbreaks [38]. OXA-23 was reported previously from two hospital centers in 
Zagreb [13] in the multicenter study conducted in 2009-2010 and it was also previously found 
in a nursing home in Zagreb [40]. 
OXA-40 group is the most prevalent CHDL among tested isolates, and this group was first 
described in the Iberian Penninsula [41], but was later identified in the Czech Republic [42] , 
USA [43], and recently in Bulgaria [44] and in the neighbouring country of Serbia [45]. 
Similar  to our isolates, the isolates from Spain and the Czech Republic belonged to IC II. 
Sequencing revealed the OXA-40 allelic variant in contrast with previous studies which 
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identified OXA-72 in other geographic regions of Croatia. The emergence of CHDL was 
associated with genetically related isolates, belonging into two PFGE clusters.  ISAba1/OXA-
51 positive isolates belonged to both groups: susceptible and intermediate susceptible, 
indicating that insertion sequence is not a good predictor of reduced susceptibility to 
carbapenems.  However, even the susceptible isolates harbouring ISAba1 upstream of the 
blaOXA-51 gene had carbapenem MICs above those in the wild type strains, similar as in 
German isolates [35] .  
Interestingly, all imipenem-susceptible A. baumannii isolates and some of the OXA-23 and 
OXA-40 positive isolates belonged to IC I. In the previous studies in Croatia, IC I was 
associated with carbapenem-susceptible isolates whereas isolates positive for OXA-40 and 
OXA-58 belonged to IC II [13].
 
PFGE patterns were correlated with resistance phenotype 
with all resistant isolates in two clusters which contained subclusters. . The fact that isolates 
with different types of CHDL (OXA-23-like and OXA-40-like) clustered together indicates 
that the oxacillinase genes were acquired after clonal spread within the hospital However, 
MLST revealed differences between isolates belonging to the same cluster.  Population 
structure of the isolates was quite variable with five different STs reported. ST 195 was 
previously reported in China and associated with OXA-23 β-lactamase in contrast with our 
study in which  this ST was found in OXA-40 positive  isolates [46-47] . In both studies 
ST195 isolates belonged to IC II.   The carbapenem-resistant isolates were mostly obtained 
from departments treating patients with severe infections.  ST 231, 775, 1094 and ST 1095 are 
reported for the first time in this study according to the bibliographical data. The population 
structure of imipenem-susceptible isolates was highly diverse.  Isolates from the previous 
study in 2009 belonged to ST1 [13] . In this study a shift to new STs was observed.  All 
imipenem-resistant isolates tested positive in the inhibitor based test with EDTA, but PCR for 
common MBLs was negative. False positive results in inhibitor based tests can occur because 
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the chelating agent itself can increase the membrane permeability, thus increasing the chance 
for a bactericial effect [48]. Moreover, false positive results were observed with combined 
disk test in detection of ESBLs  which revealed  augmentation of the inhibition zone above 5 
mm in the presence of clavulanate among carbapeneme- susceptible isolates.  Classic double 
disk synergy test turned out negative and PCR revealed no blaESBL genes.    Some of the 
isolates displayed significant difference in the MICs of imipenem and meropenem with MICs 
of meropenem being  markedly higher. The possible explanation is that the isolates with 
elevated MICs of meropenem had upregulation of efflux  pumps. Meropenem is a better 
substrate for efflux pumps, but the clarification of these mechanism was beyond this study. 
 
In conclusion, this study demonstrates the existence of several different clones of A. 
baumannii in GH Pula, which were mainly associated with IC1 and IC2 lineages. We also 
report that carbapenem-resistance was associated not only with overexpression of the intrinsic 
OXA-51 β-lactamase as was previously found in 2009-2010, but also with the acquisition of 
OXA-40 and OXA-23 which in some cases was shown to be plasmid encoded. The majority 
of resistant isolates were found to belong to the same clone.  It is reasonable to suspect a 
vertical dissemination of CHDL positive isolates. Notwithstanding, the dissemination of 
successful clones may possibly contribute to the high rates and persistance of carbapenem-
resistant A. baumannii.  
 These data demonstrate the importance of epidemiological studies to better understand the 
changing nature of carbapenem resistance. Prevention of outbreaks associated with such 
isolates should be focused on hospital hygiene measures,  screening of the patients for 
carriage of MDR A. baumannii and and restriction of carbapenem consumption.  
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FIGURE LEGEND: PFGE dendrogram of A. baumannii isolates. Cut off value of 87% was 
applied to define a clone. Hospital unit, date of isolation, specimen, sequence type,  
international clonal lineage, PFGE cluster and β-lactamase content are shown. Clusters are 
designated as I to III and subclusters as a to g.  Abbreviations: BAL-bronchoalveolar lavage 
fluid; CSF-cerebrospinal fluid;  ORL-otorhinolaryngology; ICU-intensive care unit; NRK-
neurosurgery; IC-international clonal lineage;  NT-non typeable; S- singleton 
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